About protalix biotherapeutics - PLX
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
PLX At a Glance
Protalix Biotherapeutics, Inc.
2 University Plaza
Hackensack, New Jersey 07601
| Phone | 1-201-696-9345 | Revenue | 53.40M | |
| Industry | Pharmaceuticals: Major | Net Income | 2.93M | |
| Sector | Health Technology | Employees | 213 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PLX Valuation
| P/E Current | 41.871 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 51.366 |
| Price to Sales Ratio | 2.854 |
| Price to Book Ratio | 3.30 |
| Price to Cash Flow Ratio | 17.57 |
| Enterprise Value to EBITDA | 23.575 |
| Enterprise Value to Sales | 2.305 |
| Total Debt to Enterprise Value | 0.045 |
PLX Efficiency
| Revenue/Employee | 250,699.531 |
| Income Per Employee | 13,765.258 |
| Receivables Turnover | 18.356 |
| Total Asset Turnover | 0.677 |
PLX Liquidity
| Current Ratio | 2.345 |
| Quick Ratio | 1.516 |
| Cash Ratio | 1.359 |
PLX Profitability
| Gross Margin | 54.458 |
| Operating Margin | 7.335 |
| Pretax Margin | 7.779 |
| Net Margin | 5.491 |
| Return on Assets | 3.715 |
| Return on Equity | 7.637 |
| Return on Total Capital | 6.016 |
| Return on Invested Capital | 6.864 |
PLX Capital Structure
| Total Debt to Total Equity | 12.788 |
| Total Debt to Total Capital | 11.338 |
| Total Debt to Total Assets | 7.527 |
| Long-Term Debt to Equity | 9.317 |
| Long-Term Debt to Total Capital | 8.261 |